Evaluation of The Cost Saving Potential of Introducing Benepali®, An Etanercept Biosimilar, For The Treatment of All Licensed Adult Etanercept Indications In Three Regions In Italy
Nov 1, 2016, 00:00 AM
10.1016/j.jval.2016.09.1090
https://www.valueinhealthjournal.com/article/S1098-3015(16)32456-1/fulltext
Section Title :
Disease-Specific Studies
Section Order :
1021
First Page :
A534
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32456-1&doi=10.1016/j.jval.2016.09.1090